1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine
• 英文别名: 1-pyrimidin-2-yl-4,5,6,7-tetrahydrotriazolo[4,5-c]pyridine
• 化学式: C₉H₁₀N₆
• 分子量: 202.219
• InChiKey: MMKNEJSJQJIBBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine 、 2,4-二氯苯甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (2,4-dichlorophenyl)(1-(pyrimidin-2-yl)-6,7-dihydro-1H-[1,2,3]triazolo[4,5-c]pyridin-5(4H)-yl)methanone
  参考文献：
  名称：

  Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists

  摘要：

  We describe the synthesis and SAR of 1,2,3-triazolopiperidines as a novel series of potent, brain penetrant P2X7 antagonists. Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low solubility. Further work in this series, which focused on the SAR of the N-linked heterocyde, not only increased the potency at the human P2X7R but also provided compounds with good potency at the rat P2X7R These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochemical properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.

  DOI：

  10.1021/acsmedchemlett.5b00089
• 作为产物：
  描述：

  4-氯-3-硝基吡啶 在 亚硝基叔丁烷 、 palladium 10% on activated carbon 、 rhodium contaminated with carbon 、 氢气 、 palladium diacetate 、 potassium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 9.5h， 生成 1-pyrimidin-2-yl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine
  参考文献：
  名称：

  Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists

  摘要：

  We describe the synthesis and SAR of 1,2,3-triazolopiperidines as a novel series of potent, brain penetrant P2X7 antagonists. Initial efforts yielded a series of potent human P2X7R antagonists with moderate to weak rodent potency, some CYP inhibition, poor metabolic stability, and low solubility. Further work in this series, which focused on the SAR of the N-linked heterocyde, not only increased the potency at the human P2X7R but also provided compounds with good potency at the rat P2X7R These efforts eventually delivered a potent rat and human P2X7R antagonist with good physicochemical properties, an excellent pharmacokinetic profile, good partitioning into the CNS, and demonstrated in vivo target engagement after oral dosing.

  DOI：

  10.1021/acsmedchemlett.5b00089

文献信息

• 一种P2X7受体显像剂及其制备方法
  申请人：复旦大学附属中山医院

  公开号：CN109400605A

  公开（公告）日：2019-03-01

  本发明公开了一种一种F‑18标记的P2X7受体显像剂，其为式I所示化合物18F‑(2‑氯‑3‑三氟苯基)(1‑(嘧啶‑2‑基)‑6,7‑二氢‑1H‑[1,2,3]三唑并[4,5‑c]吡啶‑5(4H)‑基)甲酮}，本发明的P2X7受体显像剂可用于鉴别诊断肺部炎症和肿瘤：
• P2X7 MODULATORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20150322062A1

  公开（公告）日：2015-11-12

  The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

  本发明涉及公式（I，IIa和IIb）的化合物：本发明还涉及包括公式（I，IIa和IIb）的化合物的制药组合物。制备和使用公式（I，IIa和IIb）的方法也在本发明的范围内。
• P2X7 modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US09066946B2

  公开（公告）日：2015-06-30

  The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

  本发明涉及公式（I、IIa和IIb）的化合物。本发明还涉及包含公式（I、IIa和IIb）的药物组成物。制备和使用公式（I、IIa和IIb）化合物的方法也在本发明的范围内。
• P2X7 modulators and methods of use
  申请人：Janssen Pharmaceutica NV

  公开号：US10112937B2

  公开（公告）日：2018-10-30

  The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention.

  本发明涉及式（I、Ia、IIa 和 IIb）化合物。本发明还涉及包含式（I、Ia、IIa 和 IIb）化合物的药物组合物。式（I、Ia、IIa 和 IIb）化合物的制造和使用方法也属于本发明的范围。
• US2014/275015
  申请人：——

  公开号：——

  公开（公告）日：——